CAISMOV24, a new human low-grade serous ovarian carcinoma cell line
- PMID: 29132324
- PMCID: PMC5683553
- DOI: 10.1186/s12885-017-3716-4
CAISMOV24, a new human low-grade serous ovarian carcinoma cell line
Abstract
Background: The spontaneous immortalization of primary malignant cells is frequently assigned to their genetic instability during in vitro culturing. In this study, the new epithelial ovarian cancer cell line CAISMOV24 was described and compared with its original low-grade serous ovarian carcinoma.
Methods: The in vitro culture was established with cells isolated from ascites of a 60-year-old female patient with recurrent ovarian cancer. The CAISMOV24 line was assessed for cell growth, production of soluble biomarkers, expression of surface molecules and screened for typical mutations found in serous ovarian carcinoma. Additionally, comparative genomic hybridization was employed to compare genomic alterations between the CAISMOV24 cell line and its primary malignant cells.
Results: CAISMOV24 has been in continuous culture for more than 30 months and more than 100 in vitro passages. The cell surface molecules EpCAM, PVR and CD73 are overexpressed on CAISMOV24 cells compared to the primary malignant cells. CAISMOV24 continues to produce CA125 and HE4 in vitro. Although the cell line had developed alongside the accumulation of genomic alterations (28 CNV in primary cells and 37 CNV in CAISMOV24), most of them were related to CNVs already present in primary malignant cells. CAISMOV24 cell line harbored KRAS mutation with wild type TP53, therefore it is characterized as low-grade serous carcinoma.
Conclusion: Our results corroborate with the idea that genomic alterations, depicted by CNVs, can be used for subtyping epithelial ovarian carcinomas. Additionally, CAISMOV24 cell line was characterized as a low-grade serous ovarian carcinoma, which still resembles its primary malignant cells.
Keywords: Ascites; Cell culture; Comparative genomic hybridization; KRAS.
Conflict of interest statement
Authors’ information
JAY and SFD are Fellowship from the Brazilian National Counsel of Technological and Scientific Development.
Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of University of Campinas (27 September 2011, 897/2011) and was registered on the Brazilian National Health Council (CAAE: 0807.0.146.000–11). Patient provided written informed consent for the use of her blood and ascites samples, and her data.
Consent for publication
A written informed consent for publication of patient’s information was provided by the patient’s next of kin.
Competing interests
Sophie Françoise Derchain is an editorial board member of BMC Cancer. The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures





References
-
- Vargas AN. Natural history of ovarian cancer. Cancer Science &Therapy. 2014;6:247–252.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials